Abingdon Health announced further expansion at its York headquarters in the UK, following further investment in state-of-the-art lateral flow automation.
Abingdon Health explains this will provide a significant increase in its manufacturing footprint, resulting in Europe’s largest capacity for rapid test manufacturing.
This news comes weeks after the UK Government announced Abingdon Health as one of the leading members of the UK Rapid Test Consortium (UK-RTC).
Earlier this year, the company announced a preliminary round of expansion in York after 90 % revenue growth in 2019, thanks to new assay developments and assay manufacturing contract wins, and the introduction of its AppDx Smartphone reader software. In April 2020, growth continued with the acquisition of a new lateral flow manufacturing facility in Doncaster, UK. This latest expansion and investment in equipment, which has been captured in a new video, comes as 2020 sees continuing high demand for Abingdon Health’s services.
Abingdon Health’s two manufacturing sites in York and Doncaster have the capacity to produce millions of rapid tests per month for clients across many industries. This adaptable, dual-site approach forms a peace-of-mind solution that assures customers receive product consistency and a security of supply during routine scheduling and spikes in demand.
Michael Hunter, Operations Director of Abingdon Health, commented: “The additional footprint and automation come at a timely moment as demand for rapid tests is growing rapidly, with the market likely to exceed $10bn globally. Our precision automation and multi-site approach means we can adapt to meet the varying manufacturing needs of our growing global client base.”
